Next day effects after nighttime treatment with zolpidem: A review

European Psychiatry

Volumn 11, Issue SUPPL. 1, 1996, Pages 21s-30s

  Unden M ^a   Roth Schechter, B ^b  

^a Sct Hans Hospital   (Denmark)

^b Boston Res and Science Consulting   (United States)

Author keywords

Benzodiazepine I receptor; Memory function; Omega I receptor selectivity; Performances; Residual effects; Short acting; Zolpidem

Indexed keywords

DIAZEPAM; FLUNITRAZEPAM; FLURAZEPAM; NITRAZEPAM; TEMAZEPAM; TRIAZOLAM; ZOLPIDEM;

ALERTNESS; CONFERENCE PAPER; HUMAN; INSOMNIA; MEMORY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT;

EID: 0030007859     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/0924-9338(96)80465-2     Document Type: Review

References (90)

1. Allain H, Lieury A, Gandon JM, Psychopharmacology of memory components. In: Hindmarch 1, Stonier PD, eds. Human Psychopharmacology: Measures and Methods, vol 4. Chichester: J Wiley & Sons Ltd, 1993;143-64
2. 3H] zolpidem binding in the rat brain: imidazopyridine wtih agonist properties at central benzodiazepine receptors. Eur J Pharmacol 1988;130: 257-63
3. Balkin TJ, O'Donnell VM, Wesensten NJ. Comparison of the day-time sleep and performance effects of zolpidem versus triazolam. Psychopharmacology 1992;107:83-8
4. Balter MB, Uhlenhuth EH. The beneficial and adverse effects of hypnotics. J Clin Psychiatry 1991;52(F)S:16-23
5. Baiter MB, Uhlenhuth EH. New epidemiological findings about insomnia and its treatment. J Clin Psychiatry 1992;53(suppl 12):34-42
6. Benavides J, Peny B, Dubois A et al. In vivo in eraction of zolpidem with central benzodiazepine (BZD) binding sites (as labeled by (3H)Ro 15-1788) in the mouse brain. Preferential affinity of zolpidem for the omega 1 (BZD 1) subtype. J Pharmacol Exp Ther 1988:245(3):1033-40
7. 3h] flumazenil binding in the rat central nervous system. J Pharmacol Exp Ther 1992;263(2):884-96
8. Benavides J, Peny B, Ruano D, Victorica J, Scatton. Comparative autoradiographic distribution of central omega (benzodiazepine) modulatory site subtypes with high, intermediate and low affinity for zolpidem and alpidem. Brain Res 1993;604(1-2):240-50
9. Bensimon G, Foret J, Warot D et al. Daytime wakefulness following a bedtime oral dose of zolpidem 20 mg, flunitrazepam 2 mg and placebo. Br J Clin Pharmacol 1990;30(3):463-9
10. Berlin I, Warot D, Hergueta T, Molinier P, Pagot C, Puech A. Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects. J Clin Psychopharmacol 1993;13(2):100-6
11. Besset A, Tafti M, Billiard M. Effects of zolpidem on sleep architecture and daytime psychomotor skills in poor sleepers. Abstract books, 10th Congress of the European Sleep Research Society, Strasbourg, 20-25 May 1990. 1990;138
12. Billard M. Evaluation of daytime wakefulness. In: Insomnie et Imidazopyridines. Amsterdam: Excerpta Medica eds. 1990;172-9
13. Bixler EO, Kales A, Brubaker BH, Kales JD. Adverse reactions to benzodiazepine hypnotics: spontaneous reporting system. Pharmacology 1987;35:286-300
14. Bixler EO, Kales A, Manfredi RL, Vgontzas AN, Tyson KL, Kales JD. Next-day memory impairment with triazolam use. Lancet 1991;337(8755):827-31
15. Bliwise D, Seidel W Karacan I et al. Daytime sleepiness as a criterion in hypnotic medication trials; comparison of triazolam and flurazepam. Sleep 1983;6:156-63
16. Borbely AA, Youmbi-Balderer G, Jaggi-Schwarz K. Zolpidem (10 mg and 20 mg): hypnotic action and residual effects after a single bedtime dose. In: Sauvanet JP, Lager SZ, Morselli PL, eds. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. New York: Raven Press eds, 1988;205-10
17. Carskadon MA, Dement WC. Sleep tendency: an objective measure of sleep loss. Sleep Res 1977;6:200
18. Carskadon MA, Dement WC, Mitler M, Roth T, Keenan S. Guidelines for the multiple sleep latency (MSLT): a standard measure of sleepiness. Sleep 1986:519-24
19. Chaumet-Riffaud A, Desforges C, Lavoisy J. Review of the post-marketing surveillance experience collected with zolpidem during the first three years after launch in Europe. Abstracts of the 11th European Congress of the ESRS, Helsinki, Finland, 5-10 July 1992. Sleep Res 1992;1(S1):40
20. Curran HV, Schiwy W, Lader M. Differential amnesic properties of benzodiazepines: a dose-response comparison of two drugs with similar half-lives, Psychopharmacology 1987;92:358-64
21. Declerck A, Ruwe F, O'Hanlon J, Wauquier A. Effects of zolpidem and flunitrazepam of women subjectively complaining of insomnia. Psychopharmacology 1992;106(4):497-501
22. Declerck A, Verbeek I, Beecher L, Schuur J. Shifts and awakenings: valuable indicators of the quality of sleep: do these parameters react differently to hypnotics? Physiol Behav 1993;54(4):815-17
23. DeJong H, Jackson J, Louwerens J. A double blind study on the residual effect on the memory of the imidazopyridine zolpidem compared placebo. Book of abstracts, WFSRS, Cannes, France, 21-25 Sept. Sleep Res 1991;20A:124
24. Dement WC. The proper use of sleeping pills in the primary care setting. J Clin Psychiatry 1992;53(suppl 12):50-6
25. Dement WC, Mitler M. It's time to wake up to the importance of sleep disorders, JAMA 1993;269(12):1548-50
26. Dockhurn RJ, Dockhurn FW. Zolpidem in the treatment of short-term insomnia: a randomized, double-blind, placebo-controlled clinical trial. Clin Neuropharmacol 1995 ; in press
27. Dujardin K, Derambure P, Guieu JD, Borderies P, Leconte P. Effects of a single dose of zolpidem 10 mg comparatively to placebo and 2 mg of flunitrazepam on cognitive process the day following the intake. Book of abstracts, WFSRS, Cannes, France, 21-25 Sept 1991. Sleep Res 1992;20A:126
28. Durand A, Thenot J, Bianchetti G, Morselli PL. Comparative pharmacokinetic profile of two imidazopyridine drugs : zolpidem and alpidem. Drug Metab Rev 1992;24(2):239-66
29. Erman M, Erwin C, Gengo F et al. Efficacy of zolpidem and temazepam in transient insomnia. Abstracts of the proceedings of the APSS Congress, Nashville, TN, USA, 30 May-4June 1995;15:8
30. Fairweather DB, Kerr JS, Hindmarch I. The effects of acute and repeated doses of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers, Eur J Clin Pharmacol 1992;43:597-601
31. Fleming J, Scharf M, Moldofsky H et al. Comparison of residual effects and efficacy of zolpidem, flurazepam, and placebo in patients with chronic insomnia. Clin Drug Invest 1995;9(6):303-13
32. Gengo FM, Owudzinski DM, Manning E. Residual Daytime Effects of Zolpidem, Temazepam and Doxylamine in Healthy Volunteers. Abstracts of the proceedings of the APSS Congress, Nashville, TN, USA, 30 May-4June 1995;15:80
33. Greenblatt DJ, Harmatz JS, Engelhardt N, Shader RI. Pharmacokinetic Determinants of Dynamic Differences Among Three Benzodiazepine Hypnotics. Arch Gen Psychiatry 1989;46:326-32
34. Griffiths AN, Marshall RW, Richens A, Saccadic eye movement analysis as a measure of drug effects on human psychomotor performance. Br J Clin Pharmacol 1984;18:73S-82S
35. Guieu JD, Duj ardin K, Derambure P, Borderies P. Comparison of acute and residual effects on memory and attention of the single dose of zolpidem (10 mg) vs zopiclone, flunitrazepam and placebo. Abstracts of the Congress of the American Sleep Disorder Association, 8th Annual Meeting, Boston, MA, USA, June 4-9, 1994. Clin Pharmacol 1994;218:427
36. Hindmarch I. Critical Flicker Fusion Frequency (CFFF). The effects of psychotropic compounds. Pharmacopsychiatria 1982;15(S1):44-8
37. Hindmarch I. Psychological performance models as indicators of the effects of hypnotic drugs on sleep. In: Hindmarch I, Ott H, Roth T, eds. Psychopharmacology Supplementum. Berlin: Sringer- Verlag, 1984
38. Hoddes E, Dement WC, Zarcone V. Quantification of sleepiness: a new approach. Psychophysiuology 1973;10:431-6
39. Hoffmann G. Lebon O, Lebuck R. Effects of zolpidem on polysomnography and daytime performance in psychophysiological insomnia. Book of abstracts, WFSRS, Cannes, France, 21-25 Sept 1991. Sleep Res 1991;20A:330
40. Jackson J, Louwerens J, Cnossen F, De Jong H. Testing the effects of the imidazopyridine zolpidem on memory: an ecologically valid approach. Human Psychopharmacol 1992;7(5):325-30
41. Johnson LC, Chernik DA. Sedative-hypnotics and human performance. Psychopharmacology 1982;76:101-13
42. Johnson LC, Chernik DA. Effects of flurazepam and midazolam on sleep and next-day performance in chronic insomniacs; report of a multicenter study. J Clin Psychopharmacol 1988;8:106-23
43. King DJ. Measures of neuroleptic effects on cognition and psychomotor performances in healthy volounteers. In: Hindmarch I, Stonier PD, eds. Human Psychopharmacology, vol 4. Chichester: J Wiley & Sons , 1993;195-209
44. Kirk T, Roache JD, Lgriffiths RR. Dose-response evaluation of the amnestic effects of triazolam and pentobarbital in normal subjects. J Clin Psychopharmacol 1990;10:161-8
45. Kleinknecht RA, Donaldson D. A review of the effects of diazepam on cognitive function and psychomotor performance. J Nerv Ment Dis 1975;161:399-411
46. Kryger MH, Steljes D, Pouliot Z, Neufeld H, Odynski T. Subjective versus objective evaluation of hypnotic efficacy: experience with zolpidem. Sleep 1991;14(5):399-407
47. Kummer J, Zander K. Polysomnographic profile of long-term efficacy of zolpidem after withdrawal in elderly psychiatric inpatients with severe insomnia. Abstacts of the 5th World Congress of Biological Psychiatry, Florence, Italy, 10-14 June 1991. Br J Psychiatry 1991;29(11S):517S
48. Kurtz D, Baas V, Rumbach L. Effets de l'administration répétée de zolpidem 10 mg sur le sommeil et la vigilance diurne chez des mauvais dormeurs. Abstracts of the Symposium Stilnox, 10th European Congress of the European Sleep Research Society, Strasbourg, France, 20-25 May 1990. Auckland: Adis eds, 1991;43-50
49. Lader M, An overview of classical and novel drugs in the treatment of insomnia. Abstracts of the 6th ECNP Congress, 10-14 October 1993, Budapest, Hungary, Eur Neuropsychopharmacology 1993;(S):20-4
50. Langer S, Arbilla S. Limitations of the benzodiazepine receptor nomenclature: a proposal for a pharmacological classification as omega receptor subtypes, Fundam Clin Pharmacol 1988;2(3):159-70
51. Langer S, Arbilla S, Sanger D et al. Differences between imidazopyridines and benzodiazepines on omega receptor selectivity: relevance to the effects on long term administration. Abstracts of the XVIth C.I.N.P. Congress, Munich, 1519 Aug 1988. Psychopharmacology 1988;96(S):90
52. Langtry H D, Benfield P. Zolpidem: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1990;40(2):291-313
53. Lister RG. The amnesic action of benzodiazepines in man. Neurosci Bio-Behav Rev 1985;9:87-04
54. Lorizio A, Terzano M, Parrino L. Controlled study of the efficacy and safety of two oral doses of zolpidem (10 and 20 mg). In: Sauvanet J P, Langer SZ, Morselli PL, eds. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach., New York: Raven Press, 1988;6:385
55. Lund R, Ruether E, Wober W. Effects of zolpidem (10 and 20 mg), lormetazepam, triazolam and placebo on night sleep and residual effects during the day. In: Sauvanet J P, Langer SZ, Morselli PL, eds. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach., New York: Raven Press, 1988;6:193-203
56. Merlotti L, Roehrs T, Koshorek G, Zorick F, Lamphere J, Roth T. The dose effects of zolpidem on the sleep of healthy normals. J Clin Psychopharmacol 1989;9:9-14
57. Monti JM. Effect of zolpidem on sleep for insomniac patients. Eur J Clin Pharmacol 1989;36:461-6
58. Morgan K. Hypnotics in the elderly, what cause for concern? Drugs 1990;40(5):688-96
59. Morgan K, Hypnotic drugs, psychomotor performance and aging. J Sleep Res 1994;3:1-15
60. Morris HH, Estes ML. Traveler's amnesia: transient global amnesia secondary to triazolam. JAMA 1987;258:945-6
61. Morselli PL, Larribaud J, Guillet P et al. Daytime residual effects of zolpidem: a review of available data. In: Sauvanet JP, Langer SZ, Morselli PL, eds. Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach, vol 6. New York: Raven Press, 1988;183-91
62. Nicholson A, Pascoe P. Hypnotic activity of an imidazopyridine (zolpidem). Br J Pharmacol 1986;21:205-11
63. Ochs R, Fillingim J, Cutler N et al. The effect of zolpidem in elderly patients with chronic insomnia. Sleep Res 1992;21:69
64. Poirrier R, Franck G, Scheldewaert R, Jolie A, Tomas M. The effect of long-term zolpidem greatment on nocturnal polysomnography and daytime vigilance in patients swith psychophysiological insomnia. Acta Ther 1994;20:77-86
65. Priest RG, Terzano MG, Parrino L, Boyer P. Efficacy of zolpidem in insomnia. Eur Psychiatry 1995;(preprint):1-10
66. Richens A, Mercer AJ, Jones DM, Griffiths A, Marshall RW. Effects of zolpidem on saccadic eye movements and psychomotor performance: a double-blind, placebo controlled study in healthy volunteers. J Clin Pharm 1993;36:61-5
67. Rittencourt P, Smith AT, Wade P, Richens A,. The relationship between peak velocity of saccadic eye movements and serum benzodiazepine concentrations. Br J Clin Pharmacol 1981;12:523-33
68. Roehrs TA, Kribbs N, Zorick F, and Roth T. Hypnotic residual effects of benzodiazepines with repeated administration. Sleep 1986;2:309-16
69. Roehrs T, Merlotti L, Zorick F, Roth T. Sedative, memory and performance effects of hypnotics. Psychopharmacology 1994;116:130-34
70. Roth T, Roehrs T, Wittig R, Zorick F. Benzodiazepines and memory. Br J Clin Pharmacol 1984;18:45S-49S
71. Roth T, Vogel G. Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo. Sleep 1995;18(4):246-51
72. Roth T, Zorick F, Witting R, Roehrs T. Pharmacological and medical considerations in hypnotic use. Sleep 1982;5:846-52
73. Sanger D, Perrault G. Morel E, Joly D, Zivkovic B. The behavioral profile of zolpidem, a novel hypnotic drug of imidazopyridine structure. Physiol Behav 1987;41:235-40
74. Sanger D, Zivkovic B. Differential development of tolerance to the depressant effects of benzodiazepine and non-benzodiazepine agonists at the omega (BZ) modulatory sites of GABA A receptors. Neuropharmacology 1992;31(7):693-700
75. Scharf MB, Mayleben DW, Kaffeman M, Krall R, Ochs R. Dose response effects of zolpidem in normal geriatric subjects. J Clin Psychiatry 1991a;52:77-83
76. Scharf MB, Mendels J, Thorpy M, Weiss B. Safety of long-term zolpidem treatment in patients with insomnia. Curr Ther Res 1994a;85(9):1100-11
77. Scharf MB, Pegram VG, Ware JC. Dose response of zolpidem in patients with chronic insomnia. Sleep Res 1990;19:90
78. Scharf MB, Roth T, Vogel G, Walsh JF. A multicenter placebo controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994b;55(5):192-9
79. Scharf M, Vogel G, Kaffeman M, Ochs R. Dose-response of zolpidem in elderly patients with chronic insomnia. Sleep Res 1991b;20:84
80. Schoch P, Moreau JL, Martin JR, Haefely WE. Aspects of benzodiazepine receptor structure and function with relevance to drug tolerance and dependence. Biochem Soc Symp 1993;59:121-34
81. Sherwood N, Kerr JS. The reliability, validity and pharmacosensitivity of four psychomotors tests. In: Hindmarch I, Stonier PD, eds. Human Psychopharmacology, vol 4. Chichester: John Wiley & Sons Ltd, 1993;1-14
82. Sicard BA, Trocherie S, Moreau J et al. Evaluation of zolpidem on alertness and psychomotor abilities among aviation ground personnel and pilots. Aviat Space Environ Med 1993;64:371-5
83. Terzano MG, Lorizio A, Farolfi A, Borghi C. Controlled study of the activity and safety of two oral doses ( 10 mg and 20 mg) of zolpidem versus placebo. Abstracts of the 11th European Congress of the ECRS, Finland 5-10 July 1992. J Sleep Research 1992; 1(S1):228
84. Thenot JP, Hermann P, Durand A et al. Pharmacokinetics and Metabolism of Zolpidem in Various Animal Species and in Humans. In: Imidazopyridines in Sleep Disorders. New York: Raven Press, 1988;139-53
85. Vaucher M, Osiek C, Schulz P. Influence of zolpidem, flunitrazepam and placebo on the cognitive and memory function in healthy subjects. In: Abstracts of the 18th Congress of the International Union of Therapeutics, Geneva, 22-24 Apr. 1987. Thérapie 1988;43(2):163
86. Vogel G, Thurmond A, Macintosh M, Clifton T. The effects of zolpidem on transient insomnia. Sleep Res 1988;17:67
87. Walsh JK, Schweitzer PK, Sugerman JL, Muehlbach MJ. Transient insomnia associated with a three-hour phase advance of sleeptime and treatment with zolpidem. J Clin Psychopharmacol 1990; 10:184-189
88. Woods JJ, Katz J, Winger G. Benzodiazepines: Use, abuse and consequences. Pharmacol Rev 1992;44:151-347
89. World Psychiatric Association. Task force on sedative hypnotics. Eur Psychiatry 1993; 8:45-9
90. Zivkovic B, Perrault G, Sanger D. Receptor subtype-selective drugs: a new generation of anxiolytics and hypnotics. In: Target Receptors for Anxiolytics and Hypnotice. Edited by S. Langer. Molecular Pharmacology to Therapeutics 1992;3:55-73